Pfizer and Allogene Agree to Collaborate on Developing Donor-derived CAR T-cell Therapies – Immuno-Oncology News
Immuno-Oncology News |
Pfizer and Allogene Agree to Collaborate on Developing Donor-derived CAR T-cell Therapies
Immuno-Oncology News Pfizer and Allogene Therapeutics have entered into a contribution agreement for Pfizer's portfolio of assets related to donor-derived chimeric antigen receptor T-cell (CAR T) therapy, a kind of cell therapy directed at blood cancers and solid tumors … Allogene Therapeutics Completes Agreement for Pfizer's Allogeneic CAR T Immuno-oncology Portfolio |
